Amphotericin B liposome preparation

    公开(公告)号:US06770290B1

    公开(公告)日:2004-08-03

    申请号:US07600154

    申请日:1990-10-19

    IPC分类号: A61K9127

    摘要: A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.

    Amphotericin B liposome preparation
    2.
    发明授权
    Amphotericin B liposome preparation 失效
    两性霉素B脂质体制剂

    公开(公告)号:US5965156A

    公开(公告)日:1999-10-12

    申请号:US469251

    申请日:1995-06-06

    摘要: A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.

    摘要翻译: 公开了一种用于将二亲性药物溶解在少量有机溶剂中用于改进的脂质体的新型组合物和方法。 磷脂酰甘油在少量有机溶剂中酸化。 然后将悬浮在有机溶剂中的两亲性药物如两性霉素B加入酸化的磷脂酰甘油中,并在磷脂酰甘油和两亲性药物之间形成可溶性复合物。 当掺入可溶性复合物的脂质体组合物水合时,仔细控制水合水性缓冲液的最终pH。 形成的两性霉素B脂质体毒性明显降低。

    Liposomal cyclosporin formulations as agents for immunosuppression and
multiple drug resistant indications
    3.
    发明授权
    Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications 失效
    脂质体环孢菌素制剂作为免疫抑制剂和多种耐药性适应症

    公开(公告)号:US5656287A

    公开(公告)日:1997-08-12

    申请号:US472635

    申请日:1995-06-07

    IPC分类号: A61K9/127 A61K38/13

    CPC分类号: A61K38/13 A61K9/127

    摘要: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratios of about 21:0.5:3:1 to 21:1.5:3:1 and 24:0.5:3:1 to about 24:1.5:3:1. The formulations are useful as immunosuppressive agents and enhancers of antineoplastic agents in drug resistant cancer cells.

    摘要翻译: 一种改进的脂质体环孢菌素治疗制剂,其包含摩尔比为约21:0.5:3:1至21:1.5:3:1和24:0.5:3:1至约24:1.5的磷脂酰胆碱,胆固醇,二肉豆蔻酰磷脂酰甘油和环孢菌素 :3:1。 该制剂作为药物抗性癌细胞中抗肿瘤剂的免疫抑制剂和增强剂是有用的。

    Antibiotic formulation and use for drug resistant infections
    7.
    发明授权
    Antibiotic formulation and use for drug resistant infections 失效
    抗生素制剂和用于耐药性感染

    公开(公告)号:US5759571A

    公开(公告)日:1998-06-02

    申请号:US84218

    申请日:1993-06-23

    IPC分类号: A61K9/127 A61K9/133

    CPC分类号: A61K31/7036 A61K9/127

    摘要: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.

    摘要翻译: PCT No.PCT / US93 / 04501 Sec。 371日期:1993年6月23日 102(e)1993年6月23日日期PCT 1993年5月11日提交的脂质体氨基糖苷制剂,其包含中性脂质,带负电荷的脂质和固醇。 该制剂含有平均粒度低于100nm的单层囊泡。 提供了含有氨基糖苷类的脂质体的方法,其中水合温度明显低于制剂的转变温度。 一种治疗药物易感和耐药细菌的方法。

    Lipid-based dispersions useful for drug delivery
    9.
    发明申请
    Lipid-based dispersions useful for drug delivery 审中-公开
    用于药物递送的基于脂质的分散体

    公开(公告)号:US20050238705A1

    公开(公告)日:2005-10-27

    申请号:US11035755

    申请日:2005-01-14

    CPC分类号: A61K9/127 A61K9/0019

    摘要: The invention provides lipid-based dispersion comprising comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.

    摘要翻译: 本发明提供基于脂质的分散体,其包含:a)磷脂酰胆碱; b)阴离子磷脂; 任选地c)总脂质重量高达1%的胆固醇; 和任选地d)治疗剂; 其中通过动态光散射测量的平均粒度小于100nm。 本发明还提供包含这种分散体的药物组合物以及在哺乳动物中产生治疗效果的方法,包括施用有效量的这种分散体。

    Liposomal cyclosporin pharmaceutical formulation
    10.
    发明授权
    Liposomal cyclosporin pharmaceutical formulation 失效
    脂质体环孢菌素药物制剂

    公开(公告)号:US5683714A

    公开(公告)日:1997-11-04

    申请号:US417487

    申请日:1995-04-05

    IPC分类号: A61K38/13 A61K9/127

    CPC分类号: B82Y5/00 A61K38/13

    摘要: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, phosphatidylglycerol and a cyclosporin in a mole ratio of from 25:3:1 to 17:3:1 is described. The formulation includes unilamellar vesicles having reduced toxicity. The formulation is used as an immunosuppressive agent and is an enhancer of the efficacy of antineoplasties for drug resistant cancer cells. A method is also provided for inhibiting the growth of cancer cells.

    摘要翻译: 描述了一种改进的脂质体环孢菌素治疗制剂,其包含摩尔比为25:3:1至17:3:1的磷脂酰胆碱,磷脂酰甘油和环孢菌素。 该制剂包括具有降低的毒性的单层囊泡。 该制剂用作免疫抑制剂,并且是用于抗药性癌细胞的抗肿瘤功效的增强剂。 还提供了抑制癌细胞生长的方法。